Hypera Sa S/Adr (HYPMY) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen, and welcome to the Hypera Pharma conference about the 2025 earnings conference call. We have Breno Oliveira, the director, and Mr. Roman, who is the director of investor relations. This is going to be recorded, and the recording can be accessed on www. All participants will be only be watching the video conference during the call. Then we will start the Q&A session where further insert instructions will be given. Information contained in this conference call may contain forecasts or statements about future expectations, which is subject to known and unknown risks and uncertainties, which may lead these expectations to not become a reality or to become substantially different from the expectations. Now I'll give the floor to Mr. Brenno Oliveira, who will begin the presentation. Please, Mr. Brenno, you may proceed. Good morning. Thank you for joining our 2025 earnings conference call. The past year was marked by important operational and financial advances, which we'll talk about throughout the presentation. I'll begin by discussing our growth on slide number three. Our sellout grew 6.8% in 2025 with an increase in market share across the categories in which we operate. The launches in 2025 contributed 1.1 percentage point to our sellout growth during the year. We were able to accelerate growth after the successful completion of our working capital optimization process in April 2025. We grew 8.3% in the third quarter 2025 and 7.4% in the fourth quarter of 2025, outperforming the growth of our addressable market in both periods. The acceleration of our sellout growth is also the result of improved inventory management. at our customers, driven by initiatives implemented during the working capital optimization process, which allowed us...